Lexicon’s Sotagliflozin Succeeds In Heart Failure Following Disappointment In Diabetes

30 May 2023

Lexicon gets broad indication across heart failure for its dual SGLT1/2 inhibitor, which will be positioned against Lilly/BI’s Jardiance and AstraZeneca’s Farxiga.

Approval — Lexicon gets sotagliflozin approval in heart failure after missing in diabetes • Source: Shutterstock

Lexicon’s Sotagliflozin Succeeds In Heart Failure Following Disappointment In Diabetes

More from New Products

More from Scrip